Compare Bank of Nova Scotia (BNS) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Cytokinetics Inc — how do they compare? Bank of Nova Scotia trades at $90.22 (market cap $108.32B), while Cytokinetics Inc trades at $75.66 (market cap $10.63B). The key difference: Bank of Nova Scotia is far larger — about 10.2× Cytokinetics Inc's market cap, and Bank of Nova Scotia pays a 3.64% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| BNS | CYTK | |
|---|---|---|
Market Cap | $108.32B | $10.63B |
Sector | Financials | Technology |
52-Week High | $90.29 | $87.26 |
52-Week Low | $56.41 | $34.31 |
Dividend Yield | 3.64% | — |
Enterprise Value | — | $10.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $89.92, up 1.54% with a bullish technical outlook supported by moving averages. The company demonstrates consistent earnings growth, beating estimates for three consecutive quarters with Q2 2026 expected at $1.53 EPS. Recent acquisition of MapleMark Bank and dividend increase to $1.14 highlight strategic growth initiatives. Valuation metrics show a P/E of 17.1 and P/B of 1.96, while maintaining strong profitability with 24.86% net income margin.
BNS presents a favorable investment case with analyst consensus leaning bullish (53% buy ratings) and technical indicators supporting upward momentum. Key opportunities include dividend growth, international expansion, and improving ROE at 11.87%. Risks include macroeconomic sensitivity, declining profit margins from 31.47% in 2022 to 20.99% in 2025, and elevated debt levels with $194.31 billion long-term obligations.
CYTK trades at $76.24, down 1.61% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, while revenue reached $88.04 million in 2025. Despite negative profitability margins, strong analyst sentiment exists with 34 buy ratings and a consensus price target of $111.14, driven by optimism around Myqorzo's commercial uptake and recent UK regulatory approval.
The outlook hinges on Myqorzo's commercial execution and pipeline expansion, offering significant upside if revenue growth accelerates. Key risks include persistent cash burn, high debt-to-asset ratio of 81.23%, and competitive pressures in the cardiovascular drug market. Investors should weigh the high valuation (P/S of 140.65) against the potential for future profitability breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
